[go: up one dir, main page]

SV2009002917A - Derivados de 3-alquilazetidina sustituidos con heterociclos - Google Patents

Derivados de 3-alquilazetidina sustituidos con heterociclos

Info

Publication number
SV2009002917A
SV2009002917A SV2008002917A SV2008002917A SV2009002917A SV 2009002917 A SV2009002917 A SV 2009002917A SV 2008002917 A SV2008002917 A SV 2008002917A SV 2008002917 A SV2008002917 A SV 2008002917A SV 2009002917 A SV2009002917 A SV 2009002917A
Authority
SV
El Salvador
Prior art keywords
disorders
treatment
useful
compounds
cbl
Prior art date
Application number
SV2008002917A
Other languages
English (en)
Inventor
Robert K Baker
Jeffrey J Hale
Shouwu Miao
Kathleen M Rupprecht
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of SV2009002917A publication Critical patent/SV2009002917A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

COMPUESTOS NOVEDOSOS DE LA FÓRMULA ESTRUCTURAL (I) SON ANTAGONISTAS Y/O AGONISTAS INVERSOS DEL RECEPTOR CANABINOIDE-1 (CBL) Y SON ÚTILES EN EL TRATAMIENTO, PREVENCIÓN Y SUPRESIÓN DE ENFERMEDADES MEDIADAS POR EL RECEPTOR CBL. LOS COMPUESTOS DE LA PRESENTE INVENCIÓN SON ÚTILES COMO FÁRMACOS QUE ACTÚAN A NIVEL CENTRAL EN EL TRATAMIENTO DE PSICOSIS, DEFICIENCIAS DE LA MEMORIA, TRASTORNOS COGNITIVOS, ENFERMEDAD DE ALZHEIMER, MIGRAÑA, NEUROPATÍA, TRASTORNOS NEUROINFLAMATORIOS QUE INCLUYEN ESCLEROSIS MÚLTIPLE Y SÍNDROME DE GUILLAIN-BARRÉ Y LAS SECUELAS INFLAMATORIAS DE LA ENCEFALITIS VÍRICA, ACCIDENTES VASCULARES CEREBRALES, Y TRAUMATISMO CRANEAL, TRASTORNOS DE ANSIEDAD, ESTRÉS, EPILEPSIA, ENFERMEDAD DE PARKINSON, TRASTORNOS DEL MOVIMIENTO, Y ESQUIZOFRENIA. LOS COMPUESTOS TAMBIÉN SON ÚTILES PARA EL TRATAMIENTO DE TRASTORNOS DE ABUSO DE SUSTANCIAS, PARA EL TRATAMIENTO DE OBESIDAD O TRASTORNOS DE LA ALIMENTACIÓN, ASÍ COMO PARA EL TRATAMIENTO DE ASMA, ESTREÑIMIENTO, PSEUDO-OBSTRUCCIÓN INTESTINAL CRÓNICA, Y CIRROSIS HEPÁTICA
SV2008002917A 2005-11-28 2008-05-28 Derivados de 3-alquilazetidina sustituidos con heterociclos SV2009002917A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74018305P 2005-11-28 2005-11-28

Publications (1)

Publication Number Publication Date
SV2009002917A true SV2009002917A (es) 2009-02-19

Family

ID=37779312

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2008002917A SV2009002917A (es) 2005-11-28 2008-05-28 Derivados de 3-alquilazetidina sustituidos con heterociclos

Country Status (15)

Country Link
EP (1) EP1954692A1 (es)
KR (1) KR20080073721A (es)
AR (1) AR058199A1 (es)
BR (1) BRPI0619018A2 (es)
CR (1) CR10014A (es)
DO (1) DOP2006000261A (es)
EC (1) ECSP088477A (es)
IL (1) IL191586A0 (es)
MA (1) MA30086B1 (es)
NO (1) NO20082919L (es)
PE (1) PE20070647A1 (es)
RU (1) RU2008126248A (es)
SV (1) SV2009002917A (es)
TW (1) TW200804317A (es)
WO (1) WO2007062193A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7906652B2 (en) 2005-11-28 2011-03-15 Merck Sharp & Dohme Corp. Heterocycle-substituted 3-alkyl azetidine derivatives
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AU2008317482A1 (en) * 2007-10-24 2009-04-30 Merck Sharp & Dohme Corp. Synthesis and crystalline forms of CB-1 antagonist/inverse agonist
WO2012031220A2 (en) 2010-09-03 2012-03-08 University Of Florida Research Foundation, Inc. Nicotine compounds and analogs thereof, synthetic methods of making compounds, and methods of use
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2805817B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation
FR2805818B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant
FR2805810B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation
CN1802351A (zh) * 2003-06-11 2006-07-12 麦克公司 被取代的3－烷基和3－链烯基氮杂环丁烷衍生物
WO2006119260A2 (en) * 2005-05-02 2006-11-09 Merck & Co., Inc. Combination of dipeptidyl peptidase-iv inhibitor and a cannabinoid cb1 receptor antagonist for the treatment of diabetes and obesity

Also Published As

Publication number Publication date
EP1954692A1 (en) 2008-08-13
DOP2006000261A (es) 2007-07-15
TW200804317A (en) 2008-01-16
PE20070647A1 (es) 2007-08-11
RU2008126248A (ru) 2010-01-10
BRPI0619018A2 (pt) 2016-11-29
ECSP088477A (es) 2008-06-30
MA30086B1 (fr) 2008-12-01
WO2007062193A1 (en) 2007-05-31
NO20082919L (no) 2008-08-27
IL191586A0 (en) 2008-12-29
KR20080073721A (ko) 2008-08-11
AR058199A1 (es) 2008-01-23
CR10014A (es) 2008-07-29

Similar Documents

Publication Publication Date Title
SV2009002917A (es) Derivados de 3-alquilazetidina sustituidos con heterociclos
ECSP056207A (es) Derivados de 3-alquil y 3-alquenilazetidina sustituidos
MA32898B1 (fr) Modulateurs allosteriques positifs du recepteur m1 d'arylmethylbenzoquinazolinone
NI201100084A (es) Antagonistas del receptor de orexina de isonicotinamida.
EA200901162A1 (ru) Производные 1,4-дизамещённого 3-цианопиридона и их применение в качестве положительных модуляторов рецептора mglur2
ECSP045289A (es) Amidas sustituidas
SV2009003417A (es) Antagonistas piridil piperidina del receptor de orexina
CO6351717A2 (es) Tripiridil carboxamida como antagonista del receptor de orexina
EP3252057A3 (en) Multicyclic compounds and methods of use thereof
EA200901160A1 (ru) Производные 3-циано-4-(4-тетрагидропиранфенил)пиридин-2-она
UY35572A (es) Nuevos agonistas del receptor de somatostatina subtipo 4 (sstr4)
MX377900B (es) Derivados de 2-(2,4,5-anilino sustituido) pirimidina como moduladores de egfr util para el tratamiento del cancer.
EA201100524A1 (ru) Азаиндазолы в качестве антагонистов рецептора ccr1
DK2049529T3 (da) Substituerede diazepan-orexin-receptor- antagonister
EA200901159A1 (ru) Производные 3-циано-4-(4-фенилпиперидин-1-ил)пиридин-2-она
MA32943B1 (fr) Piperidine spiro pyrrolidione et piperidinone substituees, leur preparation et leur utilisation therapeutique
GT200500297A (es) Sintesis asimetrica de dehidrobenzofuranos sustituidos
PH12015501793A1 (en) Bicyclic compounds
PA8604101A1 (es) Derivados de imidazol
WO2014194242A3 (en) Flt3 inhibitors and uses thereof
UY27680A1 (es) Agonistas del receptor b3 - andrenérgicos.
NZ598174A (en) Fgf receptor-activating n-acyl octasaccharides, preparation thereof, and therapeutic use thereof
EA200801302A1 (ru) Композиции и способы лечения нарушений цнс
GT200900150A (es) Nuevos compuestos azabiciclicos, un proceso para su preparacion y las composiciones farmaceuticas que los contienen.
WO2007035823A3 (en) Partial mglur5 antagonists and methods of use thereof

Legal Events

Date Code Title Description
FD Lapse